efgartigimod + telitacicept

This is a sequential biologic therapy combining two novel targeted immunotherapies for the treatment of generalized myasthenia gravis (gMG). The combination leverages complementary mechanisms of action to provide both rapid symptom relief and long-term disease control. ### Mechanism of Action Efgartigimod is an FcRn receptor antagonist that rapidly improves disease conditions by competing with endogenous IgG for FcRn binding sites, preventing IgG recycling and promoting its degradation in lysosomes[4]. This leads to a rapid reduction in circulating autoantibodies, providing quick symptom relief. However, it has a relatively short half-life of 3-5 days and requires weekly administration[4]. Telitacicept is a novel recombinant fusion protein composed of the ligand-binding domain of the TACI receptor and the Fc component of human IgG[2][6]. It works by competitively inhibiting calmodulin cyclin ligand interaction factor (TACI) to neutralize BAFF and APRIL activity, achieving multistage inhibition of B-cell and plasma cell maturation and differentiation[2]. This upstream inhibition of the immune mechanism offers a longer maintenance period compared to efgartigimod, making it more suitable for lasting response[4][6]. The sequential therapy typically involves administering efgartigimod first during acute exacerbation phases, followed by maintenance therapy with telitacicept[2]. This approach takes advantage of efgartigimod's rapid onset of action and telitacicept's longer duration of effect[2]. ### Clinical Evidence Recent studies have shown promising results for this combination therapy: - In a retrospective study, patients with gMG who received sequential treatment with efgartigimod followed by telitacicept showed stable disease status with no significant increase in MG-ADL scores after treatment[4]. - The combination therapy has demonstrated significant reductions in circulating B cells, plasma cells, and immunoglobulin G[2]. - A case report of a 37-year-old female patient with refractory gMG showed significant improvement and disease control with this combination after multiple unsuccessful therapies with immunosuppressants[2][6]. - The sequential therapy has shown a steroid-sparing effect, with significant reductions in mean daily prednisone dosage from baseline[4][8]. ### Current Research A multi-center, open-label, randomized controlled trial is currently underway to evaluate the efficacy, safety, and pharmacokinetics/pharmacodynamics of efgartigimod followed by telitacicept in patients with gMG[3]. This study aims to determine the optimal treatment strategy and timing for sequential administration. ### Considerations for Use The optimal dosing interval for bridging efgartigimod and telitacicept requires further investigation through rigorous controlled and PK/PD studies[1]. Current practice suggests administering telitacicept at a one-week interval subsequent to the administration of efgartigimod, considering the half-life of both drugs, the duration of efgartigimod's efficacy, and the drug onset time of telitacicept[1]. This combination therapy represents a promising new approach for treating refractory gMG, particularly for patients who have experienced inadequate symptom control with conventional therapies.

Brand names

VyvgartTai'ai

Other names

efgartigimod alfatelitacicept